Did the Feb 15 FDA Webinar not announce a NEW definition of the term biologic (that Dr. Sherman specifically said "would interest industry because it's new")?
Did the Feb 15 FDA Webinar not give a TRANSITION PLAN for 505-approved "biologics" (under the new definition) to 351?
Slide 18.
As of March 23, 2020, an application for a biological product approved under section 505 of the FD&C Act will be deemed a biologics license application (“BLA”) licensed under section 351 of the PHS Act.
---- Either way, the FDA appears committed to finding the most efficient pathway, but the February 15 Webinar clearly reveals NEW and relevant information. For efficiency's sake, if Copaxone is deemed a biologic under the new definition (which I don't know at this point), I suspect the approval would happen through 505(j) with a plan to transition it to 351 later on.